A detailed history of Kbc Group Nv transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Kbc Group Nv holds 4,675 shares of TGTX stock, worth $138,099. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,675
Previous 3,583 30.48%
Holding current value
$138,099
Previous $64,000 70.31%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$17.21 - $25.28 $18,793 - $27,605
1,092 Added 30.48%
4,675 $109,000
Q2 2024

Jul 17, 2024

BUY
$13.32 - $19.19 $5,820 - $8,386
437 Added 13.89%
3,583 $64,000
Q4 2023

Feb 13, 2024

BUY
$6.68 - $18.81 $21,015 - $59,176
3,146 New
3,146 $54,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.29B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Kbc Group Nv Portfolio

Follow Kbc Group Nv and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.